TABLE A7.
Incidence of Immune-Mediated Adverse Event
| Event | ABCP Arm (n = 151) | PC Arm (n = 74) | ||||
|---|---|---|---|---|---|---|
| Grade 1-2 | Grade 3 | Grade 4 | Grade 1-2 | Grade 3 | Grade 4 | |
| Total | 70 (46.3) | 10 (6.6) | 2 (1.3) | 15 (20.3) | 2 (2.7) | — |
| Adrenal insufficiency | 1 (0.7) | 2 (1.3) | — | — | — | — |
| Amylase/lipase increased | 1 (0.7) | — | — | — | — | — |
| Arthralgia | 9 (6.0) | — | — | — | — | — |
| AST/ALT increased | 12 (7.9) | 1 (0.7) | — | 8 (10.8) | 1 (1.4) | — |
| Fatigue | 17 (11.3) | 4 (2.6) | — | 7 (9.5) | 1 (1.4) | — |
| Flushing | 4 (2.6) | — | — | — | — | — |
| Hypersensitivity | — | 1 (0.7) | — | — | — | — |
| Hypoglycemia | — | — | 1 (0.7) | — | — | — |
| Hypothyroidism | 19 (12.6) | — | — | — | — | — |
| Thrombocytopenia | 1 (0.7) | — | — | — | — | — |
| Myalgia | 39 (25.8) | 2 (1.3) | 1 (0.7) | 2 (2.7) | — | — |
| Pneumonitis | 2 (1.3) | — | — | — | — | — |
| Thyroid function abnormal | 2 (1.3) | — | — | — | — | — |
| Urticaria | 4 (2.6) | — | — | — | — | — |
Abbreviations: ABCP, atezolizumab plus bevacizumab, paclitaxel, and carboplatin; PC, pemetrexed plus carboplatin or cisplatin.